Sanofi Pasteur, A Sanofi Company

This study is testing a new version of a vaccine that protects against serious bacterial infections like pneumonia and meningitis. It will compare the new 21-strain vaccine against a currently licensed 20-strain vaccine in about 1,700 healthy infants. The goal is to see if the ne…

This study is testing a new mRNA vaccine designed to protect adults aged 60 and older from two common respiratory viruses: human metapneumovirus (hMPV) and respiratory syncytial virus (RSV). Researchers will give the vaccine to about 1,530 participants to check how safe it is and…

This study is testing a new vaccine designed to protect against more strains of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. It will compare the new vaccine to an existing one in about 1,268 healthy infants, children, and adolescents. T…

This early-stage study is testing a new vaccine designed to protect against three common respiratory viruses: RSV, human metapneumovirus, and parainfluenza type 3. Researchers are giving different dose combinations to 390 adults aged 60 and older to check if the vaccine is safe a…

This study is testing a new vaccine designed to protect against five major types of meningococcal disease (A, B, C, W, Y) in children. It involves 750 healthy infants, toddlers, and children up to 9 years old. The main goals are to see how well the new vaccine triggers a protecti…

This study is testing a new mRNA vaccine designed to protect against a specific strain of bird flu (H5) that could cause a future pandemic. Researchers are giving 276 healthy adults different doses of the vaccine or a placebo to find the safest and most effective dose. The main g…